Abstract
This work investigated the spectrum-effect relationships between high performance liquid chromatography (HPLC) fingerprints and the anti-benign prostatic hyperplasia activities of aqueous extracts from Saxifraga stolonifera. The fingerprints of S. stolonifera from various sources were established by HPLC and evaluated by similarity analysis (SA), hierarchical clustering analysis (HCA) and principal component analysis (PCA). Nine samples were obtained from these 24 batches of different origins, according to the results of SA, HCA and the common chromatographic peaks area. A testosterone-induced mouse model of benign prostatic hyperplasia (BPH) was used to establish the anti-benign prostatic hyperplasia activities of these nine S. stolonifera samples. The model was evaluated by analyzing prostatic index (PI), serum acid phosphatase (ACP) activity, concentrations of serum dihydrotestosterone (DHT), prostatic acid phosphatase (PACP) and type II 5α-reductase (SRD5A2). The spectrum-effect relationships between HPLC fingerprints and anti-benign prostatic hyperplasia activities were investigated using Grey Correlation Analysis (GRA) and partial least squares regression (PLSR). The results showed that a close correlation existed between the fingerprints and anti-benign prostatic hyperplasia activities, and peak 14 (chlorogenic acid), peak 17 (quercetin 5-O-β-d-glucopyranoside) and peak 18 (quercetin 3-O-β-l-rhamno-pyranoside) in the HPLC fingerprints might be the main active components against anti-benign prostatic hyperplasia. This work provides a general model for the study of spectrum-effect relationships of S. stolonifera by combing HPLC fingerprints with a testosterone-induced mouse model of BPH, which can be employed to discover the principle components of anti-benign prostatic hyperplasia bioactivity.
Highlights
Traditional Chinese medicines (TCMs) have attracted more and more attention in recent years since they exhibit weak toxicity, affordability and complementary therapeutic effects against many diseases, and many of them were reported to have the anti-benign prostatic hyperplasia biological activities [1]
A18 indicated a relatively high influence for anti-benign prostatic hyperplasia, A14 and A17 showed a noticeable influence for anti-benign prostatic hyperplasia, A16, A4, A13, A15, A9, A1 and A10 remained a small influence for anti-benign prostatic hyperplasia, and A11, A7, A5, A3, A12, A6, A8 and A2 contained a negligible influence for anti-benign prostatic hyperplasia
The peak of the A18 is the level with the highest grey relational grade, suggesting that A18 common peak of S. stolonifera may be the active ingredient for anti-benign prostatic hyperplasia
Summary
Traditional Chinese medicines (TCMs) have attracted more and more attention in recent years since they exhibit weak toxicity, affordability and complementary therapeutic effects against many diseases, and many of them were reported to have the anti-benign prostatic hyperplasia biological activities [1]. Recent studies have shown that the extract of Saxifraga stolonifera Meerb. Has a strong effect on the treatment of benign prostatic hyperplasia (BPH) [2]. Numerous studies have reported that the prevalence of BPH was greater than 50% in men of 60 years and reaches approximately 90% by the age 85 [7,8]. The finasteride has been used for many years in the treatment of BPH and it reduced local production of the growth promoted by androgen dihydrotestosterone (DHT) [11,12]. Searching for more natural plant extracts for the management of these conditions has attracted much attention [14,15,16]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
